Assessing hypo- and hypercoagulable states in patients in ICU; aid in the rapid assessment of hemostatic imbalance and guide appropriate blood component therapy when managing perioperative bleeding in postsurgical patients; and monitoring hemostasis in patients with end-stage liver disease who need interventional procedure and/or management of major bleeding.
Thromboelastograph (TEG) is a global assessment of hemostasis and measures the ability of a whole blood sample to form a clot. The TEG assay measures the viscoelastic changes induced by clot formation and evaluates adequacy of coagulation factors and platelet function as well as the rate of formation of a clot, its strength, stability, retraction and lysis. The four key parameters of the TEG tracing are: (1) R or reaction time to initial clot formation; (2) Angle or rate of clot formation, (3) MA (maximum amplitude) or maximum strength of clot, and (4) LY30 or percent clot lysis 30 minutes after the MA.
Note: If patient is on heparin, order TEGHEP along with TEG.
Please refer to the 'TEG Manager®- Instructions for Access' for training and obtaining log-in information for remote viewing.